David A Schwartz
Overview
Explore the profile of David A Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
494
Citations
19518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malik S, Naqvi S, Shadali A, Khan H, Christof M, Niu C, et al.
Dig Dis Sci
. 2025 Mar;
PMID: 40038211
Background And Aims: Recent systematic reviews and meta-analyses (SRMAs) have shown inconsistent effectiveness of FMT among patients with IBD. This study aimed to appraise the evidence for clinically relevant outcomes...
2.
Chin D, Hernandez-Beeftink T, Donoghue L, Guillen-Guio B, Guillen-Uio B, Leavy O, et al.
medRxiv
. 2025 Feb;
PMID: 39974050
Background: Idiopathic pulmonary fibrosis (IPF) is a rare, incurable lung disease with a median survival of 3-5 years after diagnosis. Treatment options are limited. Genetic association studies can identify new...
3.
Schwartz D, Baud D, Dashraath P
Lancet Microbe
. 2025 Feb;
:101083.
PMID: 39965583
No abstract available.
4.
Oelsner E, Krishnaswamy A, Rustamov R, Balte P, Ali T, Allen N, et al.
PLoS One
. 2025 Feb;
20(2):e0316198.
PMID: 39928595
Rationale: Robust COVID-19 outcomes classification is important for ongoing epidemiology research on acute and post-acute COVID-19 conditions. Protocolized medical record review is an established method to validate endpoints for clinical...
5.
Fotook Kiaei S, Schwartz D
Expert Rev Respir Med
. 2025 Feb;
:1-12.
PMID: 39912527
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive scarring and reduced survival. The development of IPF is influenced by rare and common genetic variants, cigarette...
6.
Pingray V, Klein K, Alonso J, Belizan M, Babinska M, Alger J, et al.
EClinicalMedicine
. 2025 Feb;
80:103025.
PMID: 39896875
Background: Disease outbreaks significantly affect maternal and neonatal health. Variability in reporting health outcomes hinder evidence generation. We aimed to develop a core outcome set (COS) for maternal and neonatal...
7.
Rose J, Steele M, Kosak Lopez E, Axelsson G, Galecio Chao A, Waich A, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884764
Rationale: First-degree relatives of patients with pulmonary fibrosis (relatives) are at high risk for interstitial lung abnormalities (ILA), highlighting the need for biomarkers for risk prediction. We aimed to identify...
8.
Schwartz D
Genes (Basel)
. 2025 Jan;
16(1).
PMID: 39858634
Oropouche virus (OROV) is an orthobunyavirus endemic in the Brazilian Amazon that has caused numerous outbreaks of febrile disease since its discovery in 1955. During 2024, Oropouche fever spread from...
9.
Parian A, Schwartz D
Aliment Pharmacol Ther
. 2025 Jan;
61(5):903-904.
PMID: 39853773
No abstract available.
10.
Dashraath P, Nielsen-Saines K, Schwartz D, Musso D, Baud D
AJOG Glob Rep
. 2025 Jan;
5(1):100431.
PMID: 39810944
No abstract available.